Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Innoviva, Inc.
Public Company Financings: Theravance sold its 85% interest in Trelegy royalties from GSK and Innoviva sold its 15% interest for up to $1.8bn in total. Also, ProKidney grossed $597m from its SPAC merger, Pliant raised $200m in a post-Phase IIa offering and Marinus earned $110m in a PRV sale.
Having recently bought antibacterial developer Entasis, Innoviva adds approved antibiotic Xerava and hypotension drug Giapreza to its portfolio along with La Jolla’s established commercial organization.
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
- Other Names / Subsidiaries
- Innoviva Strategic Opportunities LLC
- Theravance, Inc.